MedTrace Logo

Copenhagen Comorbidity in HIV Infection Study

NCT02382822 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1099

Last updated 2025-04-06

No results posted yet for this study

Summary

Despite efficient antiretroviral treatment for HIV infection, decrease in life expectancy remains. Excess mortality is mainly due to non-AIDS co-morbidity including cardiovascular, pulmonary, and liver related diseases. Both HIV-unrelated and HIV-related risk factors probably contribute to this pattern. At present, most evidence regarding co-morbidity in HIV infection rely on cross-study comparisons of HIV-infected persons with published population rates and few prospective studies in U.S. cohorts. Using well characterized participants from the Copenhagen General Population Study (CGPS) as controls, we aim to include \>1500 HIV-infected persons in the COCOMO study to determine if co-morbidity is more prevalent or develops at a higher rate in HIV-infected persons. The study will asses 1) cardiovascular, 2) pulmonary and 3) liver-related co-morbidity using uniformly collected data in the two cohorts. The investigators aim to study the relative impact of HIV-unrelated and HIV-related factors on development of co-morbidity.

Conditions

Interventions

OTHER

No intervention.

Sponsors & Collaborators

  • Susanne Dam Nielsen, MD, DMSc

    lead OTHER

Principal Investigators

  • Susanne D Nielsen, Professor, MD, DMSc · Department of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet

  • Thomas L Benfield, Professor, MD, DMSc · Department of Infectious Diseases, Copenhagen University Hospital - Amager and Hvidovre

  • Klaus F Kofoed, Professor, MD, PhD, DMSc · Department of Cardiology, Copenhagen University Hospital - Rigshospitalet

  • Lars V Køber, Professor, MD, PhD, DMSc · Department of Cardiology, Copenhagen University Hospital - Rigshospitalet

  • Børge G Nordestgaard, Professor, MD, DMSc · Department of Clinical Biochemistry, Copenhagen University Hospital - Herlev and Gentofte

  • Shoaib Afzal, Professor, MD, DMSc · Department of Clinical Biochemistry, Copenhagen University Hospital - Herlev and Gentofte

Eligibility

Min Age
20 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-01
Primary Completion
2026-12-31
Completion
2035-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02382822 on ClinicalTrials.gov